Samsara Biocapital, LLC
Samsara Biocapital, LLC reported 27 holdings worth US$1.05B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Samsara Biocapital, LLC reported 27 holdings worth US$1.05B as of Sep 30, 2026. Largest: Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc. and Septerna, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 27
- Value as reported
- US$1.05B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Scholar Rock Holding Corporation | 6.9M | US$333M | 31.7% |
| Mineralys Therapeutics, Inc. | 5.87M | US$148M | 14.0% |
| Septerna, Inc. | 3.07M | US$120M | 11.4% |
| Alamar Biosciences, Inc. | 2.48M | US$84.5M | 8.0% |
| SpyGlass Pharma, Inc. | 2.11M | US$54.9M | 5.2% |
| Alumis Inc. | 7.24M | US$53.5M | 5.1% |
| Neurogene Inc. | 1.87M | US$51.9M | 4.9% |
| Kalaris Therapeutics, Inc. | 12.9M | US$37.2M | 3.5% |
| Inventiva SA | 6.31M | US$23.3M | 2.2% |
| Parabilis Medicines, Inc. | 556K | US$18M | 1.7% |
| Sutro Biopharma, Inc. | 1.06M | US$17.1M | 1.6% |
| PMV Pharmaceuticals, Inc. | 7.24M | US$12.1M | 1.1% |
| Obsidian Therapeutics, Inc. | 837K | US$11.5M | 1.1% |
| Aquestive Therapeutics, Inc. | 2.43M | US$11.3M | 1.1% |
| vTv Therapeutics Inc. | 355K | US$10.9M | 1.0% |
| Jade Biosciences, Inc. | 736K | US$10.3M | 0.98% |
| Nkarta, Inc. | 3.51M | US$9.19M | 0.87% |
| Rani Therapeutics Holdings, Inc. | 10.4M | US$8.2M | 0.78% |
| Artiva Biotherapeutics, Inc. | 955K | US$6.8M | 0.65% |
| AgomAb Therapeutics NV | 595K | US$6.6M | 0.63% |
| Eloxx Pharmaceuticals, Inc. | 400K | US$6.12M | 0.58% |
| Abivax SA | 55,095 | US$5.46M | 0.52% |
| Coherus Oncology, Inc. | 3.38M | US$4.09M | 0.39% |
| X4 Pharmaceuticals, Inc. | 1.35M | US$3.91M | 0.37% |
| Upstream Bio, Inc. | 300K | US$1.58M | 0.15% |
| TCGX Acquisition Corp. | 100K | US$1.25M | 0.12% |
| Gossamer Bio, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related